Arrowhead Pharmaceuticals Inc. (ARWR)

28.76
0.10 0.35
NASDAQ : Health Technology
Prev Close 28.86
Open 29.10
Day Low/High 28.74 / 29.10
52 Wk Low/High 10.41 / 36.80
Volume 457.50K
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 2.77B
EPS -0.70
P/E Ratio 64.22
Div & Yield N.A. (N.A)
Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

'Fast Money' Recap: Playing China Through U.S. Stocks

'Fast Money' Recap: Playing China Through U.S. Stocks

The trading panel looked at the Shanghai composite index and how investors can use U.S. stocks as a proxy.

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Interesting ARWR Put And Call Options For March 2015

Interesting ARWR Put And Call Options For March 2015

Investors in Arrowhead Research Corp saw new options begin trading this week, for the March 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ARWR Makes Bullish Cross Above Critical Moving Average

ARWR Makes Bullish Cross Above Critical Moving Average

In trading on Monday, shares of Arrowhead Research Corp crossed above their 200 day moving average of $12.66, changing hands as high as $12.84 per share. Arrowhead Research Corp shares are currently trading up about 3.2% on the day.

14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014

14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014

Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

'Fast Money' Recap: Waiting for the Dust to Settle

'Fast Money' Recap: Waiting for the Dust to Settle

The trading panel discussed the market's fall and how to hedge your positions.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Interesting ARWR Put And Call Options For August 16th

Interesting ARWR Put And Call Options For August 16th

Investors in Arrowhead Research Corp saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Arrowhead Announces New Clinical Candidate ARC-AAT For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Arrowhead Announces New Clinical Candidate ARC-AAT For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced its next clinical candidate ARC-AAT, an RNAi therapeutic designed to treat liver disease...

Today's Dead Cat Bounce Stock: Arrowhead Research (ARWR)

Today's Dead Cat Bounce Stock: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Arrowhead Research Set To Join Russell 3000 Index

Arrowhead Research Set To Join Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its...

Arrowhead Issues A Statement On Intellectual Property Protection For ARC-520

Arrowhead Issues A Statement On Intellectual Property Protection For ARC-520

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today reaffirmed its belief that it has broad access to intellectual property required to develop...

Arrowhead To Host Analyst Day To Discuss New Rare Liver Disease Candidate

Arrowhead To Host Analyst Day To Discuss New Rare Liver Disease Candidate

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day on June 19, 2014 at 12:30 p.

Arrowhead To Present At Upcoming Investor Conferences

Arrowhead To Present At Upcoming Investor Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at two upcoming investor conferences.

Arrowhead To Present At The Jefferies 2014 Global Healthcare Conference

Arrowhead To Present At The Jefferies 2014 Global Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Christopher Anzalone, Ph.

First Week of ARWR July 19th Options Trading

First Week of ARWR July 19th Options Trading

Investors in Arrowhead Research Corp saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Stock To Watch: Arrowhead Research (ARWR) In Perilous Reversal

Stock To Watch: Arrowhead Research (ARWR) In Perilous Reversal

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May.

Arrowhead Reports Fiscal 2014 Second Quarter Financial Results

Arrowhead Reports Fiscal 2014 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 second quarter ended March 31, 2014.

Arrowhead To Present At Deutsche Bank 39th Annual Health Care Conference

Arrowhead To Present At Deutsche Bank 39th Annual Health Care Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.

Arrowhead To Report Fiscal 2014 Second Quarter Financial Results

Arrowhead To Report Fiscal 2014 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 second quarter ended March...

First Week of ARWR December 20th Options Trading

First Week of ARWR December 20th Options Trading

Investors in Arrowhead Research Corp saw new options begin trading this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Stock To Watch: Arrowhead Research Corporation (ARWR) In Perilous Reversal

Stock To Watch: Arrowhead Research Corporation (ARWR) In Perilous Reversal

Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Why Arrowhead Research (ARWR) Stock is Down Today

Why Arrowhead Research (ARWR) Stock is Down Today

Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering such therapies tied to the limited number of potential relevant targets led to the move. "We have decided to significantly reduce our internal drug discovery efforts in RNA therapeutics," Novartis told FierceBiotech in a statement. "This decision was driven by ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow. In the future we will have a small group working in this field and look for partnering opportunities." Arrowhead suffered in the wake of the news, as it is involved in RNAi drug development. The stock fell more than 4.3% to hit a low of $12.55 for the day as of 2:57 p.m. on Monday.

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

TheStreet Quant Rating: C+ (Hold)